BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10360661)

  • 1. Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene.
    Liscia DS; Morizio R; Venesio T; Palenzona C; Donadio M; Callahan R
    Br J Cancer; 1999 May; 80(5-6):821-6. PubMed ID: 10360661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
    Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A
    Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
    Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
    Seitz S; Poppe K; Fischer J; Nothnagel A; Estévez-Schwarz L; Haensch W; Schlag PM; Scherneck S
    J Pathol; 2001 Jul; 194(3):318-26. PubMed ID: 11439364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
    Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors.
    Plummer SJ; Paris MJ; Myles J; Tubbs R; Crowe J; Casey G
    Genes Chromosomes Cancer; 1997 Dec; 20(4):354-62. PubMed ID: 9408751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
    Tseng SL; Yu IC; Yue CT; Chang SF; Chang TM; Wu CW; Shen CY
    Genes Chromosomes Cancer; 1997 Dec; 20(4):377-82. PubMed ID: 9408754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of BRCA2 gene in sporadic breast tumours.
    Bièche I; Noguès C; Lidereau R
    Oncogene; 1999 Sep; 18(37):5232-8. PubMed ID: 10498873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
    Patocs A; Zhang L; Xu Y; Weber F; Caldes T; Mutter GL; Platzer P; Eng C
    N Engl J Med; 2007 Dec; 357(25):2543-51. PubMed ID: 18094375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours.
    Chattopadhyay P; Rathore A; Mathur M; Sarkar C; Mahapatra AK; Sinha S
    Oncogene; 1997 Aug; 15(7):871-4. PubMed ID: 9266974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread.
    Tsuda H; Callen DF; Fukutomi T; Nakamura Y; Hirohashi S
    Cancer Res; 1994 Jan; 54(2):513-7. PubMed ID: 8275489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
    Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
    Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
    Utada Y; Haga S; Kajiwara T; Kasumi F; Sakamoto G; Nakamura Y; Emi M
    Cancer; 2000 Mar; 88(6):1410-6. PubMed ID: 10717624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
    Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
    Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer.
    Dellas A; Torhorst J; Schultheiss E; Mihatsch MJ; Moch H
    Clin Cancer Res; 2002 May; 8(5):1210-6. PubMed ID: 12006540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
    Silva JM; Silva J; Sanchez A; Garcia JM; Dominguez G; Provencio M; Sanfrutos L; Jareño E; Colas A; España P; Bonilla F
    Clin Cancer Res; 2002 Dec; 8(12):3761-6. PubMed ID: 12473587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer.
    Utada Y; Emi M; Yoshimoto M; Kasumi F; Akiyama F; Sakamoto G; Haga S; Kajiwara T; Nakamura Y
    Clin Cancer Res; 2000 Aug; 6(8):3193-8. PubMed ID: 10955803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
    Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
    Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A region close to Tp53 shows LOH in familial breast cancer.
    Luo L; Chen J; Du Q; Dumanski J; Blennow E; Kockum I; Luthman H; Lindblom A
    Int J Mol Med; 2002 Apr; 9(4):405-9. PubMed ID: 11891537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers.
    Konishi H; Takahashi T; Kozaki K; Yatabe Y; Mitsudomi T; Fujii Y; Sugiura T; Matsuda H; Takahashi T; Takahashi T
    Oncogene; 1998 Oct; 17(16):2095-100. PubMed ID: 9798680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.